UDP-glucuronosyltransferase 1A6 and 1A9 (UGT1A6 and UGT1A9)

UDP-glucuronosyltransferases 1A6 (UGT1A6) and 1A9 (UGT1A9) are essential Phase II drug-metabolizing enzymes belonging to the UGT1A subfamily. These enzymes are primarily localized in the liver and kidneys, where they catalyze the glucuronidation of a diverse array of xenobiotics and endogenous substances, including phenols, steroids, and various therapeutic agents. UGT1A6 is particularly recognized for its role in the metabolism of acetaminophen and serotonin, whereas UGT1A9 is a major contributor to the clearance of propofol, mycophenolic acid, and the active metabolite of irinotecan (SN-38). Genetic polymorphisms in these enzymes, such as the UGT1A9*22 variant, serve as critical biomarkers that influence drug exposure levels and the risk of adverse reactions, including severe chemotherapy-induced toxicity. Consequently, UGT1A6 and UGT1A9 are significant factors in pharmacogenetics and the evaluation of drug-drug interactions during clinical development.

Other names

UGT1A6UGT1A9UDP-glucuronosyltransferase 1-6UDP-glucuronosyltransferase 1-9GNT1HLUGPHLUGP1HLUGP4LUGP4UDPGT 1-6UDPGT 1-9UGT1FUGT1IPhenol-metabolizing UDP-glucuronosyltransferase

Catalyzes the transfer of a glucuronic acid moiety from UDP-glucuronic acid to a substrate molecule, increasing its water solubility for excretion.